Clinical trials: Antipsychotic Agents
Major Depressive Disorder Patients
Study to Evaluate Safety and Tolerability of FK949E in Patients With Major Depressive Disorder
The objective of the study was to evaluate the safety and plasma concentration changes of quetiapine after multiple oral administration of FK949E (extended-release formulation of quetiapine) in patients with major depressive…
- Trial name
- NCT01871974
- Testing
- FK949E
- Where
- 2 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Astellas Pharma Inc
Schizophrenia; Psychosis, Metabolic Syndrome
Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics Treated Schizophrenia Patients
Fute (Flupentixol) combined with MARTAs (Multiple-Acting Receptor Targeted Antipsychotics) drugs has its clinical efficacy toward positive symptoms and might reduce the metabolic syndrome-related factors in patients.
- Conditions
- Schizophrenia; Psychosis, Metabolic Syndrome, Flupentixol, Antipsychotic Agents
- Trial name
- NCT04898270
- Testing
- Flupentixol, Multi-acting receptor-targeted antipsychotics (MARTAs)
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Taichung Veterans General Hospital
Frontotemporal Lobar Degeneration
Treatment Study of Frontotemporal Dementia
Objectives. The proposed clinical study has two goals: First, to assess the efficacy of a central nervous system stimulant and an atypical antipsychotic in treating the behavioral symptoms of FTD and second, to further…
- Trial name
- NCT00088751
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Schizophrenia
F17464 in Acute Schizophrenia Trial
The purpose of this study is to evaluate the potential efficacy of oral F17464 in comparison to placebo over 6 weeks in patients with acute exacerbation of schizophrenia.
- Trial name
- FAST (NCT02151656)
- Testing
- F17464
- Where
- 27 sites in France, Hungary and 3 more
- Volunteers
- 158 people
- Sponsor
- Pierre Fabre Medicament
Bipolar Disorder
Dysbindin-antipsychotics Psychophamarcogenetics: a Mouse-human Translational Study Towards Personalized Healthcare in Bipolar Disorders
We will conduct an observational study involving a preliminary long-term follow-up designed to test how dysbindin-1 gene expression can modulate the efficacy of treatments with antipsychotics on clinical and neuropsychological…
- Trial name
- DYSBIP (NCT06167577)
- Testing
- Psychometric scales (BPRS, MRS, HAM-D, SES, and GAF) monthly
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Schizophrenia
A Study of the Efficacy of Fecal Microbiota Transplantation(FMT) in the Treatment of Schizophrenia
The purpose of this study was to explore whether repeated oral fecal capsules could improve outcomes in patients with schizophrenia receiving conventional antipsychotic drugs.
- Trial name
- NCT05850585
- Testing
- Fecal microbiota transplantation(FMT)
- Volunteers
- 100 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Alzheimer Disease, Dementia Alzheimers
An Electronic Clinical Decision Support Tool to Reduce Low-value Antipsychotic Prescriptions
The goal of this study will be to design, implement and test the impact of a quality improvement (QI) intervention that uses an EHR CDS tool among physicians newly ordering an antipsychotic medication for older adults with ADRD.
- Conditions
- Alzheimer Disease, Dementia Alzheimers, Dementia of Alzheimer Type
- Trial name
- NCT04851691
- Testing
- EHR CDS, Usual Care
- Where
- United States
- Volunteers
- 158 people
- Sponsor
- University of California, Los Angeles
Schizophrenia
A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia
The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with receiving multiple drugs schizophrenia.
- Trial name
- NCT01626885
- Testing
- MP-214
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- Tanabe Pharma Corporation
Delirium, Stress Disorders, Post-Traumatic
Sedation Influence on Delirium and Post-traumatic Stress-disorder as a Result of Hospitalization in Intensive Care
The aim of this study is to investigate if sedation of Intensive Care Unit (ICU) patients influences the development of delirium during their ICU stay and if incidences of delirium have an impact on the development of…
- Trial name
- NCT01291368
- Where
- 2 sites in Denmark
- Volunteers
- 248 people
- Sponsor
- University of Aarhus
Schizophrenia
Paliperidone Extended Release(ER) Effectiveness Study to Evaluate the Objective Symptom Change and Symptomatic Remission
The purpose of this study is to investigate the safety and efficacy of flexibly dosed paliperidone extended-release (ER) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment…
- Trial name
- PERFECT (NCT00761579)
- Testing
- Paliperidone
- Where
- 8 sites in South Korea
- Volunteers
- 190 people
- Sponsor
- Janssen Korea, Ltd., Korea
Dementia
Optimizing Prescribing of Antipsychotics in Long-Term Care
Inappropriate antipsychotic prescribing is a key quality indicator by which clinical outcomes might be monitored and improved in LTC.
- Trial name
- OPAL (NCT03557593)
- Testing
- Educational
- Sponsor
- Queen's University
Akathisia, Drug-Induced, Dyskinesia, Drug-Induced
Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)
This study was designed to determine if preladenant (SCH 420814, MK-3814) can reduce drug-induced involuntary movements in participants with schizophrenia or schizoaffective disorder.
- Conditions
- Akathisia, Drug-Induced, Dyskinesia, Drug-Induced, Parkinsonian Disorders
- Trial name
- NCT00686699
- Testing
- Preladenant
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC
Bipolar Disorder, Schizoaffective Disorder
Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features
Aim: In a population of first episode manic patients with psychotic features, we want to compare the side effect profile, the degree of adherence and the subjective well being, as well as the efficacy of two treatments: The…
- Trial name
- NCT00202293
- Testing
- Olanzapine, Lithium, Chlorpromazine
- Where
- Australia
- Volunteers
- 83 people
- Sponsor
- Melbourne Health
Major Depressive Disorder Patients
Study to Evaluate Safety and Tolerability of FK949E in Elderly Patients With Major Depressive Disorder
The objective of the study was to evaluate the safety and plasma concentration changes of quetiapine after multiple oral administration of FK949E (extended-release formulation of quetiapine) in elderly patients with major…
- Trial name
- NCT01903200
- Testing
- FK949E
- Where
- 2 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Astellas Pharma Inc
Schizophrenia, Sensory Gating
Remediation of Schizophrenia Sensory Gating Deficit With Aripiprazole
The purpose of this study is the use of magnetoencephalography or MEG (a machine that measures magnetic activity in your brain) and electroencephalography or EEG (a technique that measures electrical activity in your brain) to…
- Trial name
- NCT00567099
- Testing
- Aripiprzole
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- New Mexico VA Healthcare System
Weight, Body
Long-term Antipsychotic Pediatric Safety Trial
Main LAP01 study: The purpose is to evaluate the long-term pathologic weight changes associated with multi-year risperidone or aripiprazole therapy in 3 - <18-year-old children, who have varying durations of prior antipsychotic…
- Trial name
- LAPS (NCT03522168)
- Testing
- Risperidone, Aripiprazole
- Where
- 37 sites in United States
- Volunteers
- 509 people
- Sponsor
- Duke University
First Episode Psychosis
Efficacy of Treating First Episode Psychosis With Folic Acid,B12 and B6 in Addition to Antipsychotic Medication
The purpose of this study is to determine whether Vitamin B12,B6 and Folic Acid are effective with antipsychotic medication in the treatment of First Episode Psychosis.The B-complex Vitamins' homocysteine lowering properties may…
- Trial name
- NCT00202280
- Testing
- Folic Acid 5mg, Vitamin B12 0.4mg and B6 50mg
- Where
- Australia
- Volunteers
- 120 people
- Sponsor
- Melbourne Health
Schizophrenia, Psychotic Disorders
Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective Psychosis
The selection of antipsychotic in early stages of the illness is mainly determined by its clinical effectiveness. Second generation antipsychotics (SGAs) are the first line drug treatment for individuals suffering from…
- Trial name
- PAFIP2 (NCT02305823)
- Testing
- Aripiprazole, Quetiapine, Ziprasidone
- Where
- Spain
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Bipolar Disorder, Medication Adherence
CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)
This is a prospective study using customized adherence enhancement (CAE) and long-acting injectable (LAI) antipsychotic in 30 individuals with bipolar disorder (BD) at risk for treatment non-adherence.
- Conditions
- Bipolar Disorder, Medication Adherence, Medication Non Adherence
- Trial name
- NCT03408873
- Testing
- Abilify Maintena, Customized Adherence Enhancement (CAE)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Martha Sajatovic
Schizophrenia
A Study of the Potential Effects of Trimethoprim on the Pharmacokinetics of ER OROS Paliperidone
The purpose of this study is to evaluate the effects of an organic cation transporter inhibitor, trimethoprim, on the pharmacokinetics of orally administered ER OROS paliperidone and to assess the safety and tolerability of the…
- Trial name
- NCT00892541
- Testing
- ER OROS paliperidone
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.